Tocagen (NASDAQ:TOCA) was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating in a report issued on Friday.
A number of other research analysts have also weighed in on the stock. Zacks Investment Research lowered shares of Tocagen from a “hold” rating to a “sell” rating in a research note on Tuesday, November 14th. ValuEngine raised shares of Tocagen from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. Tocagen has an average rating of “Hold” and a consensus price target of $23.67.
Tocagen (NASDAQ:TOCA) opened at $12.91 on Friday. Tocagen has a 12 month low of $8.60 and a 12 month high of $17.95. The company has a quick ratio of 6.03, a current ratio of 6.03 and a debt-to-equity ratio of 0.07.
COPYRIGHT VIOLATION NOTICE: “Tocagen (TOCA) Rating Increased to Hold at BidaskClub” was reported by Markets Daily and is owned by of Markets Daily. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.themarketsdaily.com/2018/03/11/tocagen-toca-rating-increased-to-hold-at-bidaskclub.html.
Tocagen Company Profile
Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.